We also found that the PREX1 signaling hub signature indicated higher risk score for shorter survival in uveal melanoma and uterine carcinosarcoma (TCGA studies), which were not initially addressed as they were not included in the OncoLnc platform that we used for the initial screening. This evidence concerns the gene PREX1 and uterine carcinosarcoma.